No Data
No Data
ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline
Here's Why Agios Stock Plummeted More Than 20% on Monday
Improved Revenues Required Before CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock's 28% Jump Looks Justified
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround
Piper Sandler Maintains CytomX(CTMX.US) With Buy Rating, Cuts Target Price to $3.25